Merck KGaA to appeal against negative CHMP opinion on Cladribine
This article was originally published in Scrip
Merck KGaA has told the EMA that it wants a re-examination of the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) negative opinion on Cladribine Tablets for treating relapsing-remitting multiple sclerosis (RRMS).
You may also be interested in...
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.
Patient access schemes have helped the Scottish Medicines Consortium recommend rare disease products, including Regeneron/Sanofi’s Libtayo for skin cancer.